Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | HTR1D | P28221 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR5A | P47898 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665617 | 0.85 | CA12 (0.41) | CHRNA7TSHRMAPTTYRKDM4E | |
| SCHEMBL16516247 | 0.79 | CA12 (0.40) | CHRNA7TSHRMAPTTYRKDM4E | |
| SCHEMBL1046128 | 0.77 | BACE1 (0.50) | HTR2CHTR1ATAAR1HTR1DHTR2A | |
| SCHEMBL3655100 | 0.76 | ESR1 (0.42) | CHRNA7ALDH1A1BLM | |
| SCHEMBL6801484 | 0.76 | LCK (0.35) | CHRNA7TYR | |
| SCHEMBL5090081 | 0.75 | LCK (0.40) | CHRNA7MAPTTYRKDM4EALDH1A1 | |
| SCHEMBL4393973 | 0.75 | TAAR1 (0.52) | HTR2CHTR1ATAAR1HTR1DHTR2A | |
| SCHEMBL731621 | 0.75 | HMGB1 (0.55) | TAAR1HTR2ATSHRMAPTHMGB1 | |
| SCHEMBL29465001 | 0.74 | TYR (0.74) | HTR2CTAAR1TSHRCYP3A4RECQL | |
| SCHEMBL632515 | 0.74 | TYR (0.74) | HTR2CTAAR1TSHRCYP3A4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732413-B | The synthesis technique of chiral N aryl amino acids acid amides | 成都理工大学 | 2017-08-25 | — | — | CN | claimed |
| CN-104203918-B | Novel polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the beta2 adrenergic receptor. | 阿尔米雷尔有限公司 | 2017-01-18 | — | — | CN | claimed |
| CN-105732413-A | Synthetic process of chiral N-aromatic amino acid amide | 成都理工大学 | 2016-07-06 | — | — | CN | claimed |
| CN-104892532-A | Synthetic process of chiral 3-substituted 1,3,4,5-tetrahydro-1,4-benzodiazepine-2-ketone | UNIV CHENGDU TECHNOLOGY | 2015-09-09 | — | — | CN | claimed |
| CN-101674853-A | Amino acid lipids and uses thereof | NASTECH PHARM CO | 2010-03-17 | — | — | CN | claimed |
| EP-0038071-B1 | NEW UNLABELLED AND RADIOACTIVE LABELLED DERIVATIVES OF BUTYLAMINO PROPIOPHENONE, THEIR PREPARATION, IMMUNOGENS OBTAINED FROM THE UNLABELLED DERIVATIVES AND A PROCESS FOR IMMUNOGEN PREPARATION, ANTISERA RAISED USING THE IMMUNOGENS AND A METHOD FOR RAISING ANTISERA, A RADIOIMMUNOASSAY METHOD AND A TEST KIT FOR USE IN THE ASSAY METHOD | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-11-14 | — | — | EP | claimed |
| CN-106922129-B | Methods of conjugating polypeptides | 免疫医疗有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-110650947-B | Methods and molecules | 免疫医疗有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110650947-A | Methods and molecules | 免疫医疗有限责任公司 | 2020-01-03 | — | — | CN | disclosed |
| CN-109689010-A | Blue powder and its purposes in cosmetics | 莱雅公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-107531778-A | Antigen-conjugated immunoreagents | 赛尔伊迪克斯公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107501114-A | A kind of synthetic method of chiral alpha aminoamide compound | 大连理工大学 | 2017-12-22 | — | — | CN | disclosed |
| CN-106459205-A | Conjugated compounds comprising cysteine-engineered antibodies | 免疫医疗有限责任公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2006069175-A2 | ANTIFUNGAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS | POLYTECHNIC UNIVERSITY (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060035875-A1 | Remedy for hormone-dependent cancer | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1568381-A1 | REMEDY FOR HORMONE-DEPENDENT CANCER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050164955-A1 | Antifungal properties of various forms of sophorolipids | SyntheZyme, LLC | 2005-07-28 | — | — | US | disclosed |
| WO-2004044216-A1 | ANTIMICROBIAL PROPERTIES OF VARIOUS FORMS OF SOPHOROLIPIDS | POLYTECHNIC UNIVERSITY (US) | 2004-05-27 | — | — | WO | disclosed |
| CN-1035179-C | New indol derivatives | ALMIRALL LAB (ES) | 1997-06-18 | — | — | CN | disclosed |
| CN-1087629-A | new indole derivatives | ALMIRALL LAB (ES) | 1994-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035875-A1 | Remedy for hormone-dependent cancer | STS, CYP21A2, SHBG | CHRNA7 4170/4885HTR2C 2225/4885HTR1A 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.